KBP-042

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2016
0120142016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
KBP-042 is a dual amylin and calcitonin receptor agonist that increases glucose tolerance and insulin action and reduces body… (More)
Is this relevant?
2016
2016
OBJECTIVE In this study, KBP-042, a dual amylin- and calcitonin-receptor agonist, was investigated as a treatment of obesity and… (More)
Is this relevant?
2015
2015
KBP-042 is a synthetic peptide dual amylin- and calcitonin-receptor agonist (DACRA) developed to treat type 2 diabetes by… (More)
Is this relevant?
2014
2014
The present study investigated a novel oral dual amylin and calcitonin receptor agonist (DACRA), KBP-042, in head-to-head… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?